AstraZeneca: CHMP greenlights ovarian cancer drug
(CercleFinance.com) - AstraZeneca and MSD (Merck outside of North America) report that the CHMP has recommended marketing authorisation of Lynparza (olaparib) in the EU for maintenance treatment in the first line, with bevacizumab, for advanced ovarian cancer.
This favourable opinion concerns patients with advanced ovarian cancer with HRD (recombinant homologous deficient)-positive, a tumour that affects half women with advanced ovarian cancer.
It is based on the PAOLA-1 Phase III study, which showed that patients treated with Lynparza and bevacizumab had no progression of the disease for a median of 37.2 months, compared with 17.7 months for bevacizumab alone.
Copyright (c) 2020 CercleFinance.com. All rights reserved.